[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"copd-exacerbation-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:copd-exacerbation-acute":201},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,81,108,133,159,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100647067","phase-2-rademikibart-iv-for-acute-asthma-and-copd-exacerbation-100647067",false,"NCT07705737","Rademikibart IV for Acute Asthma and COPD Exacerbation","A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Asthma and or COPD With Type 2 Inflammation","Inclusion Criteria - Asthma cohort\n\n* Body weight of ≥40 kg and BMI ≤45 kg\u002Fm2 at SV1a.\n* Physician-diagnosed asthma\n* Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication.\n* Must have experienced at least 1 asthma exacerbation requiring the use of systemic corticosteroids.\n* Participants in a stable condition, must have a historical peripheral blood eosinophil count of ≥250 cells\u002FμL and\u002For FeNO ≥ 25 ppb.\n* Current acute asthma exacerbation requiring an urgent healthcare visit for treatment.\n* Peripheral blood eosinophil count of ≥300 cells\u002FµL as part of the assessment of an index acute asthma exacerbation.\n* Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation.\n* FEV1 ≥30% predicted.\n\nExclusion Criteria - Asthma cohort\n\n* Regular use of immunosuppressive medication.\n* Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension.\n* Current or former smoker, with a smoking history of ≥5 pack-years if \\\u003C30 years old or ≥10 pack-years if ≥30 years old\n* COPD and other clinically significant pulmonary disease other than asthma.\n* Known or suspected history of immunosuppression.\n* History of known immunodeficiency disorder or hepatitis B or C.\n* History of alcohol abuse and\u002For drug abuse.\n* Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix or other malignancies treated with apparent success with curative therapy.\n* Female participant who is pregnant, lactating or breast-feeding.\n* Recent receipt of any marketed nonbiologic drug that modulates type 2 cytokines.\n* Recent receipt of any marketed biologic drug or any investigational biologic for asthma or other diseases.\n* Recent live, attenuated vaccinations or planned live, attenuated vaccinations during the trial.\n* Participants that have been recently treated with bronchial thermoplasty.\n* Recent receipt of any investigational nonbiologic drug.\n* A recent chest X-ray or computed tomography with findings that are inconsistent for an asthmatic population.\n\nInclusion Criteria - COPD cohort\n\n* Body weight of ≥45 kg and BMI ≤45 kg\u002Fm2\n* Physician-diagnosed COPD\n* Must have experienced at least 1 COPD exacerbation requiring the use of systemic corticosteroids.\n* Participants in a stable condition must have a historical peripheral blood eosinophil count of ≥250 cells\u002FμL and\u002For FeNO ≥ 25 ppb.\n* Current or former smoker with a history of smoking of ≥10 pack-years.\n* Current acute COPD exacerbation requiring an urgent healthcare visit for treatment.\n* Peripheral blood eosinophil count of ≥300 cells\u002FμL as part of the assessment of the index acute COPD exacerbation.\n* Requires systemic corticosteroids as standard of care treatment in the urgent healthcare setting for the current acute COPD exacerbation.\n\nExclusion Criteria - COPD cohort\n\n* Regular use of immunosuppressive medication 12 weeks or 5 half-lives prior to approximately 12 weeks or 5 half-lives, whichever is longer.\n* Current diagnosis or a history of asthma, according to the Global Initiative for Asthma; or participants with a current diagnosis or history of Asthma COPD Overlap Syndrome.\n* Other respiratory disorders that might compromise the safety of the participant or affect the interpretation of the results.\n* Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension. Cardiac arrhythmias including paroxysmal atrial fibrillation.\n* Transient ischemic attack or stroke \\\u003C6 months from Screening Visit; hospitalization for any cardiovascular or cerebrovascular event \\\u003C6 months from Screening Visit.\n* Known or suspected history of immunosuppression.\n* History of known immunodeficiency disorder or hepatitis B or C.\n* History of alcohol abuse and\u002For drug abuse.\n* Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success.\n* Chronic treatment with long-term oxygen therapy or nocturnal oxygen therapy required for \\>15 hours a day.\n* Participants on long-term macrolide.\n* Current acute COPD exacerbation for which SoC was started \\>48 hours prior to Screening.\n* A recent chest X-ray or computed tomography scan reveals evidence of clinically significant abnormalities or pulmonary infection.\n* Female participant who is pregnant, lactating or breast-feeding.\n* Receipt of any marketed nonbiologic drug that modulates type 2 cytokines 30 days or 5 half-lives prior to SV1b, whichever is longer.\n* Receipt of any marketed or any investigational biologic for COPD or other diseases within 16 weeks or 5 half-lives, whichever is longer.\n* Live, attenuated vaccinations within 4 weeks prior to screening or planned live, attenuated vaccinations during the trial.\n\nThe above inclusion and exclusion criteria are not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","ALL","18 Years","85 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation",[27,28],"Asthma Acute","COPD Exacerbation Acute",[30,31,32,33,34,35,36,37,38,39,40],"Acute exacerbation","Asthma","Asthma exacerbation","CBP-201","Rademikibart","Connect Biopharma","COPD exacerbation","COPD acute","COPD","COPD flare","Asthma attack","NOT_YET_RECRUITING","2026-07-10",{"date":44,"type":45},"2026-07-15","ACTUAL",{"date":47,"type":21},"2026-07-30",{"date":49,"type":21},"2027-01",{"name":51,"class":52},"Connect Biopharm LLC","INDUSTRY",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100440187","evaluation-of-high-dose-prednisolone-pharmacokinetics-in-the-acute-and-chronic-setting-100440187","NCT05012033","Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","EHD-Pred PK","Inclusion Criteria:\n\n* Aged 18 - 75 years\n* Male or female\n* Participants who are otherwise healthy enough to participate, as determined by pre-study medical history\n* Participants who are able and willing to give written informed consent to participate in the study\n* Group A only: Patients requiring acute (\\\u003C5 days) high dose (minimum 30mg) oral prednisolone therapy for antiinflammatory purposes in either an inpatient or outpatient setting.\n* Group B only: Minimum of 1 month duration of high dose prednisolone (\\>30mg) if in the chronic use group.\n* Group C only: Patients started on high dose methylprednisolone (\\>3 day course) or prolonged courses of dexamethasone.\n\nExclusion Criteria:\n\n* Participants with a diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Unable to give informed consent.\n* Taking supplements or herbal medications that the participant is unwilling or unable to stop prior to and during the study period e.g. St John's Wort (may decrease prednisolone levels), Cat's claw, Echinacea (immunomodulatory properties).\n* Currently taking medications that alter CYP3A4 metabolism of glucocorticoids that the participant is unwilling or unable to stop prior to and during the study period e.g. phenytoin, phenobarbital, rifampicin, rifabutin, carbamazepine, primidone, aminogluethimide, itraconazole, ketoconazole, ciclosporin or ritonavir.\n* Pregnancy. Females of child-bearing age will be asked to provide a urine sample for a pregnancy test at each visit.\n* History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or compromise the safety of the participant.","75 Years",{"count":63,"type":21},120,"OBSERVATIONAL","This is a pilot study to investigate serum prednisolone profiles in:\n\n* Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting.\n* Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone.\n\nThe study will comprise 3 groups, including those started on high doses of prednisolone acutely in an inpatient or outpatient setting, participants on chronically high doses, and those receiving a several week course of high dose methylprednisolone or dexamethasone.\n\nThe study aims to measure prednisolone levels at a number of time points to investigate serum profile differences in those receiving prednisolone acutely compared with longer term steroid use. Further samples will be taken to characterise additional metabolic changes.",[67,68,28,31,69],"Thyroid Eye Disease","Vasculitis","Inflammatory Disease","RECRUITING","2026-03-24",{"date":73,"type":45},"2026-03-27",{"date":75,"type":45},"2023-04-12",{"date":77,"type":21},"2030-12-31",{"name":79,"class":80},"Imperial College London","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100598807","phase-1-a-repeat-ascending-dosing-study-of-the-safety-and-clinical-activity-of-r-3750-in-patients-with-mild-to-moderate-copd-100598807","NCT07076290","A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD","R-3750-01-LU","Inclusion Criteria:\n\n* Subjects with a clinically documented history of COPD for at least 1 year in accordance with the definition by the American Thoracic Society\u002FEuropean Respiratory Society.\n* Subjects must present with the following: a measured pre and post-salbutamol Forced expiratory volume in one second\u002F Forced vital capacity (FEV1\u002FFVC) ratio of \\\u003C0.70 to confirm the diagnosis of COPD; a measured post-salbutamol FEV1\\>20% and ≤80% of predicted normal values\n* Baseline mMRC dyspnea score 1 to 3\n* Post-bronchodilator FEV1 \\> 50% predicted (GOLD COPD grade 1-2)\n* Smoking pack years ≥ 10 years\n* Age ≥ 40 years\n* Acceptable standard-of-care COPD maintenance therapy includes long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), inhaled corticosteroids (ICS), or combinations thereof (e.g., dual LABA\u002FLAMA, or triple LABA\u002FLAMA\u002FICS therapy). The patient must have been on a stable dose and regimen for at least 4 weeks prior to screening with no changes anticipated during the study unless medically necessary.\n* A history of ≥ 1 exacerbations in the last 12 months\n* Be able to provide written consent; compliant with study procedures and study visits.\n\nExclusion Criteria:\n\n* Patients whose treatment is considered palliative (life expectancy \\\u003C12 months) Comorbid severe lung disease, such as bronchiectasis, pulmonary fibrosis\n* Current smoker or cessation within 3 months of screening, or current use of vaping device\n* Patients with pneumonia or COPD exacerbation or lower respiratory infections within the 4 weeks prior to study Day 1\n* Uncontrolled co-morbid conditions, such as diabetes mellitus, hypertension and heart failure \\[e.g. New York Heart Association (NYHA) class III (e.g. less than ordinary activity causes fatigue, palpitation, or dyspnea), and class IV (e.g. Symptoms of heart failure at rest)\\] that will affect the study.\n* Myocardial infarction, unstable angina or stroke within 12 months prior to screening\n* Diagnosis of malignancy within 5 years of study Day 1(except for excised localized carcinoma of skin not including malignant melanoma)\n* Clinically significant ECG changes, which in the opinion of investigator warrants further investigations\n* Evidence of alcohol, drug or solvent abuse.\n* Pregnant, breastfeeding, or lactating women. Women of child-bearing potential (i.e. not surgically sterilized or post- menopausal) must have a negative blood serum pregnancy test performed at the screening visit and must agree to use two methods of birth control (one of which must be a barrier method) for at least 3 months past the last day on the study.\n* Participation in an interventional clinical study within 3 months of study Day 1 or receipt of any investigational medicinal product within 3 months or 5 half- lives.\n* Lung volume reduction surgery or bronchoscopic lung volume reduction within the last 12 months.\n* Historical or current evidence of clinically significant neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease\u002Fcondition exacerbated during the study.\n* Other conditions that could lead to elevated eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis with Polyangiitis, or Eosinophilic Esophagitis.\n* Cirrhosis or current unstable liver disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice. Stable noncirrhotic chronic liver disease (including Gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis B or C -e.g., presence of hepatitis B surface antigen \\[HbsAg\\] or positive hepatitis C antibody test result) is acceptable if the participant otherwise meets entry criteria.\n* Active blood born infection (e.g. HIV, Hepatitis A, B or C)\n* Current or recent (\\\u003C2 weeks) treatment with oral steroids, theophylline, chronic azithromycin or other methylxanthines, roflumilast, or Dupixent\n* Current infection or antibiotic treatment\n* Use of probiotics within 2 weeks of study Day 1\n* Subjects with a current diagnosis of asthma (those with a prior history are eligible if they meet inclusion criteria for a current diagnosis of COPD)\n* Subjects receiving treatment with oxygen more than 4.0 Litres\u002Fminute (L\u002Fmin). While breathing supplemental oxygen, subjects should demonstrate oxyhemoglobin saturation greater than or equal to 89 percent.","40 Years","82 Years",{"count":91,"type":21},27,[93],"PHASE1","The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)",[96,97,28],"COPD (Chronic Obstructive Pulmonary Disease)","COPD Exacerbation",[38],"2026-01-27",{"date":101,"type":45},"2026-01-29",{"date":103,"type":21},"2026-09-01",{"date":105,"type":21},"2028-12-31",{"name":107,"class":52},"Rise Therapeutics LLC",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":53},"100493343","phase-4-standard-vs-targeted-oxygen-therapy-prehospital-for-chronic-obstructive-pulmonary-disease-100493343","NCT05703919","Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease","STOP-COPD","Inclusion Criteria:\n\n* Patients over the age of 40\n* EMT or Paramedic suspected AECOPD\n* Confirmed suspicion of COPD\n\nExclusion Criteria:\n\n* Bronchospasm due to asthma, allergic reaction or non-COPD conditions\n* Known or suspected pregnancy\n* Prehospital Non-invasive, invasive or assisted bag mask ventilation\n* Allergy to inhaled bronchodilators (Salbutamol)\n* Inter-hospital transfer\n* More than 2 doses (5 mg salbutamol) inhalation drug, acute treatment by EMS (emergency medical service) personnel, before allocated treatment is initiated\n* Suspicion of acute coronary syndrome",{"count":116,"type":21},1888,[118],"PHASE4","The STOP-COPD trial is a randomized, patient-blinded, prehospital clinical trial designed to evaluate the effect of titrated oxygen therapy compared to standard oxygen treatment in patients with suspected acute exacerbation of chronic obstructive pulmonary disease (AECOPD) treated with inhaled bronchodilators. The primary objective is to determine whether a titrated oxygen strategy targeting SpO₂ 88-92% can reduce 30-day mortality compared to the current standard practice using 100% compressed oxygen as a nebulizer driver.",[97,28],[122,97,123,38],"Titrated Oxygen","Prehospital","2025-06-08",{"date":126,"type":45},"2025-06-10",{"date":128,"type":45},"2025-06-02",{"date":130,"type":21},"2028-05-31",{"name":132,"class":80},"Central Denmark Region",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":4},"100582915","study-on-acupuncture-treatment-of-chronic-airway-diseasesasthma-and-chronic-obstructive-pulmonary-disease-100582915","NCT06869525","Study on Acupuncture Treatment of Chronic Airway Diseases(Asthma and Chronic Obstructive Pulmonary Disease)","Study on the Efficacy and Mechanism of Acupuncture in the Acute Stage of Chronic Airway Diseases (Asthma and Chronic Obstructive Pulmonary Disease)","Inclusion Criteria:\n\n* Meets the diagnostic criteria for acute attack of asthma\u002FAECOPD;\n* Age range from18 years to 80 years(asthma) and 40 yesrs to 80 years(COPD);\n* The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients with combined pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis and other pulmonary diseases;\n* Patients with severe cardiovascular and cerebrovascular diseases (such as malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.);\n* Patients with severe liver diseases (such as liver cirrhosis, portal hypertension and bleeding caused by esophageal and gastric fundus varices) and severe kidney diseases (such as dialysis, kidney transplantation, etc.);\n* Patients with impaired consciousness or various mental disorders who are unable to communicate normally;\n* Pregnant and lactating women;\n* Those who are currently participating in other clinical trials within 1 month before enrollment;\n* Patients with contraindications to acupuncture (such as severe allergic or infectious skin diseases);","80 Years",{"count":142,"type":21},576,[144],"NA","For patients in the acute phase of chronic airway diseases, on the basis of guideline-directed treatment, the experimental group was given acupuncture treatment, while the control group was given sham acupuncture treatment. The treatment lasted for one week, followed by a 13-week follow-up. For asthma and COPD, PEF and CAT were respectively used as the primary outcome measures to evaluate the clinical efficacy and safety of acupuncture. Based on the improvement of the primary outcome measures, the advantageous population was identified. The mechanism by which acupuncture reduces airway mucus hypersecretion was preliminarily explained.",[28,27],[28,27,148,149],"Acupuncture","Randomized Controlled Trial","2025-03-05",{"date":152,"type":45},"2025-03-11",{"date":154,"type":21},"2025-03",{"date":156,"type":21},"2027-12",{"name":158,"class":80},"Henan University of Traditional Chinese Medicine",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":53},"100541557","multiparametric-home-telemonitoring-of-patients-with-chronic-obstructive-pulmonary-disease-exacerbation-100541557","NCT06331416","Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation","Inclusion Criteria:\n\n1. Able to understand and sign the informed consent form.\n2. Already established diagnosis of COPD according to Global Initiative for Obstructive Lung Disease (GOLD) guidelines.\\[13\\]\n3. Diagnosis of COPD exacerbation at admission, according to GOLD guidelines.\\[13\\]\n4. Arterial partial pressure of oxygen (PaO2) \\\u003C 60 mmHg in ambient air at rest at admission and arterial partial pressure of oxygen (PaO2) \\> 60 mmHg in ambient air at rest at discharge, if not on long-term oxygen therapy on ventilation.\n5. Arterial partial pressure of oxygen (PaO2) \\\u003C 55 mmHg on usual oxygen supplement (L\u002Fmin) and arterial partial pressure of oxygen (PaO2) \\> 60 mmHg on oxygen supplement at discharge, if already on long-term oxygen therapy on ventilation.\n\ng) Age \\\u003C= 90 and \\>= 18 years old at randomization.\n\nExclusion Criteria:\n\n1. Heart failure as the main cause of acute respiratory failure\n2. Acute pulmonary embolism\u002Fchronic pulmonary thromboembolism\n3. Interstitial lung disease as the main cause of acute respiratory failure\n4. Pneumonia as the main cause of acute respiratory failure\n5. Chronic renal failure with dialysis dependence\n6. Immunosuppression (i.e. cancer on treatment, post-organ transplantation, HIV-positive, on immunosuppressant therapy)\n7. Progressive neuro-muscular disorders\n8. Cognitively impaired, dementia or decompensated psychiatric disorder\n9. Quadriplegia\u002FHemiplegia or quadriparesis\u002Fhemiparesis\n10. Do-not-resuscitate order\n11. Any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with the protocol","90 Years",{"count":167,"type":21},60,[144],"Chronic obstructive pulmonary disease (COPD) exacerbations are risk factors for disease progression and short-term re- hospitalizations. We propose a randomized controlled trial to evaluate the efficacy of a one-device multiparameter telemonitoring in reducing functional decline, symptoms, and risk of re-hospitalization of patients discharged after hospitalization for exacerbated COPD.",[38,28],"2024-04-30",{"date":173,"type":45},"2024-05-02",{"date":175,"type":45},"2024-03-29",{"date":177,"type":21},"2026-09-30",{"name":179,"class":80},"University of Trieste",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":188,"targetDuration":190,"studyType":64,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":53},"100495681","copd-icu-multicentre-prospective-observational-register-100495681","NCT05734365","COPD-ICU Multicentre Prospective Observational Register","Epidemiological, Clinical and Biological Characteristics and Therapeutic Management of ICU Patients With Severe Acute Exacerbation of COPD. Evaluation of the Prognosis and the Factors Associated With Survival Multicentre Prospective Observational Register","COPD-ICU","Inclusion Criteria:\n\n1. Age ≥ 40 years old\n2. COPD documented or strongly suspected\n\n   * Chronic respiratory symptoms (dyspnoea, cough and\u002For sputum)\n   * Exposure to a known risk factor for COPD (such as tobacco smoke)\n   * If available, respiratory function tests showing non- or partially reversible obstructive syndrome (post-bronchodilator ratio FEV1\u002FCV \\\u003C 0.7)\n3. Severe acute exacerbation, defined as a worsening of the patient's usual respiratory symptoms with signs of acute respiratory distress (polypnoea ≥ 30 cycles.min-1 or use of accessory respiratory muscles) and\u002For hypercapnic acidosis (with PaCO2 ≥ 45 mmHg and pH ≤ 7.35)\n4. Admission to an ICU, or a dedicated respiratory intensive care unit\n\nExclusion Criteria:\n\n1. Known asthma (according to the criteria of the international \"Global Initiative for Asthma\" guidelines)\n2. Patient refusal to participate (information note, application for non-opposition)",{"count":189,"type":21},500,"1 Year","COPD is one of the leading causes of morbidity, mortality and health care utilisation worldwide. Currently, COPD is the third leading cause of death worldwide and is therefore a major public health problem. Projections show an increase in the prevalence and burden of COPD in the coming decades due to ageing populations and continued exposure to risk factors.\n\nIn patients with COPD, mortality due to exacerbations is about 35%. Exacerbations represent the most important respiratory event in the history of this chronic disease and are of major socio-economic interest (about 50-75% of healthcare expenditure in this disease).\n\nIn the most severe cases, COPD exacerbations lead to respiratory distress with hypercapnic ventilatory acidosis requiring ventilatory support. These most severe episodes are common, accounting for 20% of exacerbations and are a signal of advanced disease, with a high risk of future hospitalisations and a limited long-term prognosis.\n\nDespite progress in management, the mortality of these severe acute exacerbations is around 15% in the ICU and 20% in hospital. The long-term prognosis following hospitalisation for an acute exacerbation of COPD is poor with a 5-year mortality of around 50%. On the one hand, the means and treatments likely to improve the prognosis of these patients are of great medical and socio-economic interest, on the other hand, it seems important to identify the elements that may be associated with management failure and to treat them where appropriate.\n\nThus, improving scientific knowledge thanks to prospective data, evaluating the different characteristics and prognosis of patients hospitalised for a severe acute exacerbation of COPD seems, in the 21st century, a major axis in order to continue to optimise the individual management of these patients but also collectively, given the COPD public health burden.",[28],"2023-02-16",{"date":195,"type":45},"2023-02-17",{"date":197,"type":45},"2022-11-01",{"date":156,"type":21},{"name":200,"class":80},"Versailles Hospital","Copd Exacerbation Acute"]